The XPO1 Inhibitor KPT-8602 Synergizes with Dexamethasone in Acute Lymphoblastic Leukemia
Sign Up to like & getrecommendations! Published in 2020 at "Clinical Cancer Research"
DOI: 10.1158/1078-0432.ccr-20-1315
Abstract: Purpose: KPT-8602 (Eltanexor) is a second-generation exportin-1 (XPO1) inhibitor with potent activity against acute lymphoblastic leukemia (ALL) in preclinical models and with minimal effects on normal cells. In this study, we evaluated whether KPT-8602 would… read more here.
Keywords: kpt 8602; acute lymphoblastic; xpo1 inhibitor; lymphoblastic leukemia ... See more keywords
Abstract LB-B14: Pediatric Preclinical Testing Consortium evaluation of the second-generation selective inhibitor of nuclear export (SINE) compound KPT-8602
Sign Up to like & getrecommendations! Published in 2018 at "Molecular Cancer Therapeutics"
DOI: 10.1158/1535-7163.targ-17-lb-b14
Abstract: Introduction: KPT-8602 is a second-generation SINE compound that specifically blocks exportin-1 (XPO1) cargo interactions. XPO1 is a nuclear export receptor, a critical regulator of cell proliferation and survival, that is characterized as the sole transporter… read more here.
Keywords: sine compound; second generation; kpt 8602;
Abstract 1587: Disruption of nuclear export with selinexor or KPT-8602 reduces androgen receptor expression and leads to potent anti-tumor activity in preclinical models of androgen-independent prostate cancer
Sign Up to like & getrecommendations! Published in 2017 at "Cancer Research"
DOI: 10.1158/1538-7445.am2017-1587
Abstract: Metastatic castration resistant prostate cancer (mCRPC) is an advanced form of prostate cancer (PC) associated with poor prognosis. Approximately 20 - 40% of mCRPCs are androgen-independent and do not respond to treatment with abiraterone or… read more here.
Keywords: prostate; androgen independent; selinexor kpt; cancer ... See more keywords
Abstract 4049: The synergistic effect of melphalan and XPO1 inhibition in preclinical models of multiple myeloma
Sign Up to like & getrecommendations! Published in 2017 at "Cancer Research"
DOI: 10.1158/1538-7445.am2017-4049
Abstract: Introduction: Significant increases in response/survival have been seen over the past several years; however, multiple myeloma (MM) remains incurable. In this study we have demonstrated that the XPO1 inhibitors (XPO1i), selinexor (SEL) and KPT-8602, sensitize… read more here.
Keywords: xpo1i mel; multiple myeloma; melphalan; preclinical models ... See more keywords
The XPO1 Inhibitor KPT-8602 Ameliorates Parkinson’s Disease by Inhibiting the NF-κB/NLRP3 Pathway
Sign Up to like & getrecommendations! Published in 2022 at "Frontiers in Pharmacology"
DOI: 10.3389/fphar.2022.847605
Abstract: Exportin 1 (XPO1) is an important transport receptor that mediates the nuclear export of various proteins and RNA. KPT-8602 is a second-generation inhibitor of XPO1, demonstrating the lowest level of side effects, and is currently… read more here.
Keywords: kpt; kpt 8602; parkinson disease; inhibitor ... See more keywords